MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC

被引：0
|
作者：
Mamdani, H. [1 ]
Kim, S. [1 ]
Gentzler, R. [2 ]
Furqan, M. [3 ]
Shields, M. D. [4 ]
Jalal, S. I. [4 ]
机构：
[1] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[2] Univ Virginia, Charlottesville, VA USA
[3] Univ Iowa, Iowa City, IA USA
[4] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Small cell lung cancer; Monalizumab; Extensive stage;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.13A.03
引用
收藏
页码：S207 / S207
页数：1
相关论文
共 50 条
  • [21] Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy
    Jotte, R.
    Conkling, P.
    Reynolds, C.
    Klein, L.
    Fitzgibbons, J. F.
    McNally, R.
    Renschler, M.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy
    Owonikoko, Taofeek
    Ready, Neal
    Postmus, Pieter
    Reck, Martin
    Peters, Solange
    Pieters, Anne
    Selvaggi, Giovanni
    Fairchild, Justin
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S306 - S307
  • [23] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.
    Chen, Yuanbin
    Paz-Ares, Luis G.
    Dvorkin, Mikhail
    Trukhin, Dmytro
    Reinmuth, Niels
    Chiara Garassino, Marina
    Statsenko, Galina
    Voitko, Oleksandr
    Hochmair, Maximilian
    Ozguroglu, Mustafa
    Verderame, Francesco
    Havel, Libor
    Losonczy, Gyorgy
    Conev, Nikolay
    Hotta, Katsuyuki
    Ji, Jun Ho
    Broadhurst, Helen
    Byrne, Natalie
    Thiyagarajah, Piruntha
    Wade Goldman, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
    Chen, Yuanbin
    Paz-Ares, Luis
    Reinmuth, Niels
    Garassino, Marina Chiara
    Statsenko, Galina
    Hochmair, Maximilian J.
    Oezgueroglu, Mustafa
    Verderame, Francesco
    Havel, Libor
    Losonczy, Gyoergy
    Conev, Nikolay, V
    Hotta, Katsuyuki
    Ji, Jun Ho
    Spencer, Stuart
    Dalvi, Tapashi
    Jiang, Haiyi
    Goldman, Jonathan W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 3 (06):
  • [25] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [26] Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial.
    Cheng, Ying
    Wang, Jie
    Zhou, Caicun
    Yao, Wenxiu
    Wang, Qiming
    Min, Xuhong
    Chen, Gongyan
    Xu, Xingxiang
    Li, Xingya
    Xu, Fei
    Fang, Yong
    Yang, Runxiang
    Yu, Guohua
    Gong, Youling
    Zhao, Jun
    Fan, Yun
    Liu, Quan
    Cao, Lejie
    Yao, Yu
    Liu, Yunpeng
    Li, Xiaoling
    Wu, Jingxun
    He, Zhiyong
    Lu, Kaihua
    Jiang, Liyan
    Yu, Huiqing
    Hu, Chengping
    Zhao, Wenhua
    Zhao, Jian
    Wu, Gang
    Huang, Dingzhi
    Chen, Chengshui
    Ding, Cuimin
    Zhang, Baihong
    Wang, Xiuwen
    Luo, Hui
    Li, Baolan
    Zhang, Ben
    Li, Haowen
    Ma, Ke
    CANCER RESEARCH, 2022, 82 (12)
  • [27] First-line sintilimab combined with platinum-based chemotherapy in extensive stage small cell lung cancer: A phase II study and post-hoc biomarker analysis.
    Su, ChunXia
    Xie, Mengqing
    Zhao, Jing
    Chu, Xiangling
    Liu, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial
    Maluf, Fernando Cotait
    Trindade, Karine
    Almeida Preto, Daniel D.
    Marques Monteiro, Fernando Sabino
    Luz, Murilo
    Beato, Patricia Milhomem
    Bastos, Diogo Assed
    Holanda Soares, Joao Paulo
    Lopes dos Santos, Victor Marcondes
    Werneck De Carvalho, Luis Eduardo
    Borges Muniz, David Queiroz
    Racy, Douglas
    Halabi, Susan
    Rebelatto, Taiane Francieli
    Werutsky, Gustavo
    de Jesus, Rafaela Gomes
    Fay, Andre P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Durvalumab ± tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study
    Grohe, C.
    Paz-Ares, L. G.
    Dvorkin, M.
    Chen, Y.
    Hotta, K.
    Trukhin, D.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Ji, J. H.
    Voitko, O.
    Poltoratskiy, A.
    Verderame, F.
    Havel, L.
    Bondarenko, I.
    Armstrong, J.
    Byrne, N.
    Jiang, H.
    Goldman, J. W.
    Reinmuth, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 149 - 149
  • [30] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 36-monthoverall survival from the Phase 3 CASPIAN study
    Paz-Ares, Luis
    Schulz, Christian
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 148 - 149
12345